Evotec AG (EVT.DE)

19.34 +0.07 (+0.36%) At close: 05:35PM CEST

Evotec AG

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 5,067

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.	Chairman of Management Board & CEO	1.32M	N/A	1968
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	804k	N/A	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	N/A	1970
Dr. Matthias Evers Ph.D.	Chief Bus. Officer & Member of Management Board	636k	N/A	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	N/A	N/A	1974
Ms. Anja Bosler	Principal Accounting Officer and Sr. VP of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Sr. VP and Global Head of Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Sr. VP & Head of Global Corp. Communications & Marketing	N/A	N/A	N/A
Ms. Monika Conradt	Global Head of HR	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate governance

Evotec AG’s ISS governance QualityScore as of 1 September 2023 is 5. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.